EW
Edwards LifesciencesPrevious close
92.01
Change
−2.43 / −2.57%
P/E (TTM) ?
53.7
Market Cap
$53.6B
1M
+6.59%
S&P 500 −0.91% over same period
Volume / Avg Volume
6.0M / 3.0M
2.03× average
Latest earnings analysisFY2026 Q2Reported 2026-07-23
Edwards Lifesciences Q2 FY26: sales up 13.6%, adjusted EPS $0.78
Edwards beat its own sales guidance and edged past the $0.7627 adjusted EPS consensus, so the operating story is strong even though GAAP EPS fell to $0.42 from $0.56. The gap between $0.42 and $0.78 is mostly a $188.2 million tax charge, not a change in the business. Read revenue growth and adjusted EPS as the operating signal here, and treat GAAP net income as a one-off tax story.
Read the full analysis →Revenue$1.74BYoY +13.60%
EPS (non-GAAP)$0.78Beatest. $0.76
Next-quarter revenue guidance$1.67B ±2.4%YoY −4.10%
Next-day move−1.42%
Recent Earnings
Click to read the FinDog analysis| Period | Reported | Revenue | Analysis |
|---|---|---|---|
| FY2026 Q2 Quarter ended 2026-06 | 2026-07-23 | $1.7B | Read analysis → |
| FY2026 Q1 Quarter ended 2026-03 | 2026-04-23 | $1.6B | Pending |
| FY2025 Q4 Quarter ended 2025-12 | 2026-02-10 | $6.1B | Pending |
| FY2025 Q3 Quarter ended 2025-09 | 2025-10-30 | $1.6B | Pending |
| FY2025 Q2 Quarter ended 2025-06 | 2025-07-24 | $1.5B | Pending |
| FY2025 Q1 Quarter ended 2025-03 | 2025-04-23 | $1.4B | Pending |
Decision Panel
Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market dataValuation
P/E is at percentile 100 of its 5-year rangeExpensive
5-year range 10.2 – 49.8 · Median 32.1
Last 4 quarters: $1.2B in buybacks + $0 in dividends, 2.25% of market cap combined
P/E (TTM)
53.7
P/B
5.1
P/S
8.3
PEG
3.62
Earnings Reaction
Over the last 6 reports, the stock moved ±3.9% on average on the first trading day after, rising 4 times
Most recent −1.42%
Guidance Credibility
Of the last 2 next-quarter revenue guides, 2 were met; actual results averaged 3.6% above guidance
Insider Trading
View all →Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions
Buy 0 · $0.00MSell 7 · $3.5MNet selling $3.5M
- 10-08Lippis Daniel J.CVP, TAVRSell$0.05M619 shares · Avg price 85.65
- 09-11Lippis Daniel J.CVP, TAVRSell$0.05M619 shares · Avg price 87.51
- 08-31Dahl Andrew M.SVP, Corporate ControllerSell$0.05M544 shares · Avg price 91.06
- 08-28Bruls AnnetteCVP, EMEACLASell$0.24M2,644 shares · Avg price 89.98
- 08-26Markowitz WayneCVP, JAPACSell$0.11M1,240 shares · Avg price 91.47
- 08-26Chopra DaveenCVP, TMTT, Surgical & IHFMSell$2.9M31,800 shares · 2 trades · Avg price 91.02
- 08-11Lippis Daniel J.CVP, TAVRSell$0.06M619 shares · Avg price 92.03
Multi-Quarter Financial Trends
View all quarters →Last 12 quarters · As reported by the company
| Quarter | Revenue ($B) | YoY | Gross Margin | Net Income ($B) | EPS |
|---|---|---|---|---|---|
| FY2026 Q2 | 1.74 | +13.6% | 77.5% | 0.24 | 0.42 |
| FY2026 Q1 | 1.65 | +16.7% | 78.0% | 0.38 | 0.66 |
| FY2025 Q4 | 1.57 | +13.3% | 78.1% | 0.09 | 0.16 |
| FY2025 Q3 | 1.55 | +14.7% | 77.8% | 0.29 | 0.50 |
| FY2025 Q2 | 1.53 | +11.9% | 77.5% | 0.33 | 0.56 |
| FY2025 Q1 | 1.41 | +6.2% | 78.7% | 0.36 | 0.61 |
| FY2024 Q4 | 1.39 | +9.4% | — | 0.39 | 0.65 |
| FY2024 Q3 | 1.35 | +8.9% | 80.6% | 3.07 | 5.13 |
| FY2024 Q2 | 1.37 | +7.1% | 79.9% | 0.37 | 0.61 |
| FY2024 Q1 | 1.33 | +8.9% | 78.4% | 0.35 | 0.58 |
| FY2023 Q4 | 1.27 | +194.6% | — | 0.37 | 0.61 |
| FY2023 Q3 | 1.24 | −5.7% | 79.8% | 0.38 | 0.63 |
| Ticker | P/E | Revenue YoY | Gross Margin | 1M | View |
|---|---|---|---|---|---|
| EW | 53.7 | +13.6% | 77.5% | +6.59% | Neutral |
| LLY | 50.2 | +38.6% | 83.9% | +22.51% | Bullish |
| JNJ | 41.3 | +5.9% | 68.1% | +3.20% | Bullish |
| ABBV | 81.4 | +10.2% | 74.7% | +12.73% | Bullish |
| UNH | 23.0 | +0.4% | 88.1% | +10.87% | Bullish |
| MRK | 117.2 | +5.1% | 73.5% | +2.90% | Neutral |
| TMO | 36.4 | +9.1% | — | +3.25% | Neutral |
| AMGN | 28.5 | +9.5% | 72.0% | +10.56% | Bullish |
| GILD | — | +6.8% | 81.1% | +14.51% | Neutral |